Advantage Alpha Capital Partners LP Fennec Pharmaceuticals Inc. Transaction History
Advantage Alpha Capital Partners LP
- $419 Million
- Q3 2024
A detailed history of Advantage Alpha Capital Partners LP transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 52,876 shares of FENC stock, worth $210,975. This represents 0.06% of its overall portfolio holdings.
Number of Shares
52,876Holding current value
$210,975% of portfolio
0.06%Shares
1 transactions
Others Institutions Holding FENC
# of Institutions
64Shares Held
14.9MCall Options Held
10KPut Options Held
83.8K-
Southpoint Capital Advisors LP New York, NY4.08MShares$16.3 Million0.57% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$9.61 Million27.51% of portfolio
-
Solas Capital Management, LLC Darien, CT1.92MShares$7.67 Million7.68% of portfolio
-
Dg Capital Management, LLC New York, NY1.52MShares$6.07 Million4.41% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$4.74 Million0.0% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $104M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...